Invivyd (NASDAQ:IVVD) Upgraded at Morgan Stanley

Morgan Stanley upgraded shares of Invivyd (NASDAQ:IVVD) from an equal weight rating to an overweight rating in a research report released on Tuesday morning, MarketBeat reports. The firm currently has $10.00 target price on the stock, up from their previous target price of $4.00.

Separately, HC Wainwright reaffirmed a buy rating and set a $15.00 price objective on shares of Invivyd in a research note on Monday, March 25th.

Invivyd Price Performance

NASDAQ:IVVD opened at $4.44 on Tuesday. The firm has a market capitalization of $488.89 million, a P/E ratio of -2.86 and a beta of 0.60. Invivyd has a 1-year low of $0.98 and a 1-year high of $5.20. The company’s fifty day moving average price is $4.15 and its 200-day moving average price is $2.88.

Insider Transactions at Invivyd

In other news, major shareholder Adimab, Llc sold 5,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $3.95, for a total transaction of $19,750,000.00. Following the sale, the insider now owns 21,687,906 shares of the company’s stock, valued at approximately $85,667,228.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 19.10% of the company’s stock.

Institutional Investors Weigh In On Invivyd

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Invivyd by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,513,706 shares of the company’s stock valued at $9,904,000 after acquiring an additional 24,692 shares during the period. Goldman Sachs Group Inc. grew its stake in Invivyd by 135.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 54,137 shares of the company’s stock valued at $213,000 after acquiring an additional 31,186 shares during the period. Barclays PLC acquired a new stake in Invivyd in the 4th quarter valued at $285,000. Bridgeway Capital Management LLC grew its stake in Invivyd by 14.8% in the 4th quarter. Bridgeway Capital Management LLC now owns 510,900 shares of the company’s stock valued at $2,013,000 after acquiring an additional 66,000 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Invivyd in the 4th quarter valued at $342,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.